Dr. Davison is currently Chairman and CEO of HistoSonics, a developer of histotripsy therapeutic ultrasound technology based in Ann Arbor, Michigan. Mr. Davison founded HistoSonics in late 2009 with management and scientists at the University of Michigan to commercialize the U of M's non-invasive ultrasound surgical ablation technology, Histotripsy.
Dr. Davison is also President of MedTech Innovations, LLC which he founded in January, 2007 to help scientists and entrepreneurs bridge the gap between medical technology and business. Dr. Davison was Chairman of Board of Directors of Chart Medical (2007 - 2011), which he co-founded in 2007 to reintroduce Chymopapain injection for treatment of lumbar disc herniation. Prior to founding MedTech Innovations, Dr. Davison was President and CEO of Sontra Medical Corporation (NASDAQ SC: SONT). Dr. Davison led the Company's transition from an early stage R&D company to develop the first transdermal glucose monitor for critical care. Sontra merged with Echo Therapeutics in late 2006. Prior to joining Sontra, Dr. Davison was the Chief Executive Officer of Endius, Inc., which he co-founded in 1997. At Endius, Dr. Davison invented and commercialized the first endoscopic spine fusion technology and surgical procedure. Endius was acquired by Zimmer Holdings in June 2007. Prior to Endius, Dr. Davison was the co-founder and President of UltraCision, the market leader in advanced directed energy surgical systems. While at UltraCision, he led a team of engineers to develop the Harmonic Scalpel. UltraCision and the Harmonic Scalpel were sold to Ethicon Endosurgery, a Johnson & Johnson company in late 1995. Today, the Harmonic Scalpel sales exceed $1 billion worldwide.
Mr. Clapper is presently the Chief Executive Officer of Minerva Surgical, Inc., a medical device start-up company based in the Silicon Valley; Cupertino, CA. Mr. Clapper also serves as a member of the board of directors at Silicon Valley Bank, NeoMend, Baxano, and Dfine. Mr. Clapper holds a B.S. in Marketing from Bowling Green State University.
Mr. Clapper began his medical device career at Johnson and Johnson. During 16 years at J&J, he held positions from Sales Representative to Vice President of Sales and Marketing, and Member of the Board of Directors of Ethicon Endo-Surgery. In 1993, he became the President and CEO of Focal, a biomaterials company in Boston. Focal completed its Lehman Brothers/Piper Jaffray lead IPO in December 1997. In 1999, Mr. Clapper began serving as President and CEO of Novacept in Palo Alto, CA until the acquisition in 2004 by Cytyc Corporation for $325 million. Novacept manufactured and marketed the Novasure System. In 2005, he became the President and CEO of SurgRx, a surgical sealing and cutting device company in Redwood City, CA. In August of 2008, SurgRx signed a definitive agreement to be acquired by Ethicon Endo-Surgery, a Johnson and Johnson company.
Until their acquisitions, Mr. Clapper held board positions at St. Francis Medical Technologies and Conor MedSystems. Companies at which Mr. Clapper has served, either as CEO or board member, have been acquired over the last four years for a cumulative value of $2.73 billion.
Dr. Kriewall is presently a Program Director at the Kern Family Foundation, a non-profit organization committed to driving entrepreneurial education in engineering pedagogy at private universities across the United States. He is also President Emeritus of Wisconsin Lutheran College located in Milwaukee, Wisconsin.
From 2000 to 2003, Dr. Kriewall was Vice President of Research and Development at Medtronic Xomed, where his teams developed surgical tools for ear-nose-throat (ENT) surgery. Earlier in his career he was Director of Research and Development at Medtronic Perfusion Systems, and Technical Manager at 3M Cardiovascular Systems, where he was responsible for the development of cardiopulmonary bypass systems. While at 3M, he was the technical lead for the first-ever cochlear implant to receive FDA approval in 1984.
Dr. Kriewall holds Bachelor's and Master's degrees in electrical and computer engineering from the University of Michigan and Stanford University, respectively, and a Ph.D. in biomedical engineering from the University of Michigan where he served on their faculty for eight years before entering industry in 1981. He left Michigan as an Associate Professor of Obstetrics and Gynecology where he conducted research in the field of perinatal medicine.
Dr. Kriewall is a Fellow of the American Institute of Engineering in Medicine and Biology. He has authored 19 publications in scientific journals, presented at numerous national and international meetings, written chapters in medical text books, and he is a co-inventor named on five patents.
Dr. Davis is a highly regarded orthopedic surgeon at the Cleveland Clinic as well as a team physician for the United States Olympic Team. He was an Academic All-American and Captain of one of Michigan State's most successful football teams. He has been involved in multiple medical and metabolic technologies including those related to sports drinks and the metabolic needs of high performance athletes as well as computerized software design for maximized bio mechanical muscle training.
Dr. Deirmengian is a practicing orthopaedic surgeon specializing in total hip and total knee replacements. He completed his BA in chemistry at Princeton University in 1992, his MD at Harvard Medical School in 1996, his residency in orthopaedic surgery at the University of Pennsylvania in 2005 and his Fellowship in Adult Reconstructive Surgery of the Hip and Knee at Rush University Medical Center in Chicago in 2006. His numerous awards and achievements include: The Mark Coventry Award for outstanding science research-given by the Knee Society for his research in using biomarkers to identify infection in the human joint, The DeForest Willard award for outstanding chief resident at the University of Pennsylvania, the Orthopaedic Research and Education Fund award for outstanding research and the Leonard Marmor Award for joint arthroplasty. In 2009 he was selected as a "John Insall Traveling Fellow" and completed a month long fellowship with the top total knee surgeons throughout the United States. He has numerous publications for various research projects throughout his career.
Dr. Krieg is an Associate Professor of Orthopaedic Surgery at the University of Washington and Harborview Medical Center in Seattle, Washington. He is a board certified surgeon whose practice focuses on orthopedic trauma, including care of complex fractures and management of multiply injured patients. An active researcher and educator, he teaches nationally and internationally. He currently serves on the North American Musculoskeletal Trauma Education Committee of the Arbeitsgemeinshaft fur Osteosyntesefragen (AO). As an innovator, he has seen two of his ideas for medical devices successfully developed and brought to market. He is a frequent industry collaborator and invited speaker.
Dr. Shannon is a cardiovascular surgeon with William Beaumont Hospital in Royal Oak, Michigan. Dr. Shannon has authored numerous publications in cardiovascular and general surgery, and is a reviewer for the Annals of Thoracic Surgery. Dr. Shannon is a well-known surgical valve design innovator, with particular expertise in mitral and tricuspid valve systems, percutaneous/minimally accessible mitral annular remodeling devices, aortic valves, and minimally invasive devices used in atrial ablation procedures. Dr. Shannon sits on the scientific advisory board of Micardia, a BioStar Ventures portfolio company, and is a consultant to Medtronic, Datascope, and Pequot Capital Management.
Dr. Thomas is a practicing plastic surgeon in Salt Lake City, Utah. He attended the University of Utah for undergraduate and medical school, graduating in 1974. He completed his residency training in general surgery and plastic surgery at UCLA Medical Center, and completed an additional fellowship in craniofacial surgery under the tutelage of Dr. Henry Kawamoto, one of the world's leading experts in this field, at UCLA.
From 1990 to 1993, in addition to maintaining his private practice, he became a full time member of the faculty of the University of Utah School of Medicine as Associate Professor of Surgery in Plastic Surgery. Dr. Thomas has served on the Board of Directors of Interplast, Inc., a non-profit organization providing reconstructive surgery to patients in underdeveloped countries, and has volunteered services on several trips to South and Central America, Asia, and Africa.
He is the past President of the Utah State Plastic Surgery Society and past Chairman of the Division of Plastic Surgery at LDS Hospital and Primary Children's Medical Center.
Dr. Thomas is Board Certified by the American Board of Plastic Surgery, and is a member of the American Society of Plastic Surgeons, American Society for Aesthetic Plastic Surgery, American Society of Maxillofacial Surgery, Utah State Plastic Surgery Society, Salt Lake Surgical Society, and he is a Fellow of the American College of Surgeons.
Dr. Wapner is a practicing ophthalmologist in Salt Lake City, Utah. He completed his undergraduate studies at the University of Pennsylvania where he graduated Magna Cum Laude. He continued his studies at Columbia University where he received his doctorate in medicine.
Dr. Wapner served his internship at the University of Utah/LDS Hospital in Salt Lake City. Following his internship he went on to become Chief Resident at the Edward S. Harkness Eye Institute at Columbia University.
Dr. Wapner serves as a clinical instructor in Ophthalmology at the University of Utah. He is the Medical Director at the Physicians Surgery Center, as well as the Chairman of the Department of Ophthalmology at St. Marks Hospital.
Dr. Wapner is board certified by the American Academy of Ophthalmology. He is a Fellow of the American College of Surgeons, as well as a member of the American Academy of Ophthalmology, American Board of Ophthalmology, and American Society of Cataract and Refractive Surgeons.